| Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation … TE Carew, DC Schwenke, D Steinberg Proceedings of the National Academy of Sciences 84 (21), 7725-7729, 1987 | 1367 | 1987 |
| Pioglitazone for diabetes prevention in impaired glucose tolerance RA DeFronzo, D Tripathy, DC Schwenke, MA Banerji, GA Bray, ... New England Journal of Medicine 364 (12), 1104-1115, 2011 | 956 | 2011 |
| Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and … AD Watson, N Leitinger, M Navab, KF Faull, S Hörkkö, JL Witztum, ... Journal of Biological Chemistry 272 (21), 13597-13607, 1997 | 943 | 1997 |
| Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. DC Schwenke, TE Carew Arteriosclerosis: An Official Journal of the American Heart Association, Inc …, 1989 | 577 | 1989 |
| Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. DC Schwenke, TE Carew Arteriosclerosis: An Official Journal of the American Heart Association, Inc …, 1989 | 406 | 1989 |
| Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. JD Wagner, TB Clarkson, RW St Clair, DC Schwenke, CA Shively, ... The Journal of clinical investigation 88 (6), 1995-2002, 1991 | 342 | 1991 |
| Determinants of Bioactivity of Oxidized Phospholipids: Specific Oxidized Fatty Acyl Groups at the sn-2 Position G Subbanagounder, N Leitinger, DC Schwenke, JW Wong, H Lee, ... Arteriosclerosis, thrombosis, and vascular biology 20 (10), 2248-2254, 2000 | 276 | 2000 |
| NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019 | 261 | 2019 |
| Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus EA Schwartz, J Koska, MP Mullin, I Syoufi, DC Schwenke, PD Reaven Atherosclerosis 212 (1), 217-222, 2010 | 212 | 2010 |
| Endothelial dysfunction in response to psychosocial stress in monkeys. WB Strawn, G Bondjers, JR Kaplan, SB Manuck, DC Schwenke, ... Circulation Research 68 (5), 1270-1279, 1991 | 206 | 1991 |
| Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis PD Reaven, TE Moritz, DC Schwenke, RJ Anderson, M Criqui, R Detrano, ... Diabetes 58 (11), 2642-2648, 2009 | 187 | 2009 |
| Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. S Parthasarathy, MT Quinn, DC Schwenke, TE Carew, D Steinberg Arteriosclerosis: An Official Journal of the American Heart Association, Inc …, 1989 | 187 | 1989 |
| Exenatide protects against glucose-and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans J Koska, M Sands, C Burciu, KM D’Souza, K Raravikar, J Liu, S Truran, ... Diabetes 64 (7), 2624-2635, 2015 | 167 | 2015 |
| Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes J Koska, EA Schwartz, MP Mullin, DC Schwenke, PD Reaven Diabetes care 33 (5), 1028-1030, 2010 | 157 | 2010 |
| A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance AB Goldfine, PR Conlin, F Halperin, J Koska, P Permana, D Schwenke, ... Diabetologia 56, 714-723, 2013 | 143 | 2013 |
| Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations DC Schwenke, SR Behr Circulation research 83 (4), 366-377, 1998 | 139 | 1998 |
| Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial JJ Zhou, DC Schwenke, G Bahn, P Reaven Diabetes Care 41 (10), 2187-2194, 2018 | 136 | 2018 |
| A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from … LM Belalcazar, DM Reboussin, SM Haffner, RC Hoogeveen, AM Kriska, ... Diabetes care 33 (11), 2297-2303, 2010 | 133 | 2010 |
| Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors A Saremi, DC Schwenke, TA Buchanan, HN Hodis, WJ Mack, MA Banerji, ... Arteriosclerosis, thrombosis, and vascular biology 33 (2), 393-399, 2013 | 131 | 2013 |
| Quantification in vivo of increased LDL content and rate of LDL degradation in normal rabbit aorta occurring at sites susceptible to early atherosclerotic lesions. DC Schwenke, TE Carew Circulation research 62 (4), 699-710, 1988 | 127 | 1988 |
